Cross Skin Reactivity to Tyrosine Kinase Inhibitors in a Patient with Chronic Myelogenous Leukemia

Abstract

<p class="MsoNormal"> <span lang="EN-US">Tyrosine kinase inhibitors (TKI) targeting the bcr-abl protein, c-kit and the platelet-derived growth factor receptors, are significant part of the pathogenic therapy of chronic myelogenous leukemia. A broad spectrum of cutaneous side effects ha</span><span lang="EN-US">s</span><span lang="EN-US"> been described with the clinical use of imatinib mesylate, ranging from various acute rashes to toxic epidermal ne</span><span lang="EN-US">crolysis. Herein, a case of cross skin toxicity to TKI in a patient with chronic myelogenous leukemia is presented. In the course of imatinib mesylate therapy the patient developed a grade 4 diffuse lichenoid drug eruption. Six months after switching to nilotinib, hyperpigmented macules and patches spread over his trunk and extremities. To date, few cases of c</span><span lang="BG">ross </span><span lang="EN-US">skin reactivity to imatinib and nilotinib</span><span lang="EN-US"> </span><span lang="EN-US">have been described, none of which showing different clinical phenotypes. Further understanding of the underlying mechanisms</span><span lang="EN-US"> and</span><span lang="EN-US"> leading to the development of skin rashes from different class of TKI is important to highlight new drug targets and modify the current therapies to a level of maximal efficacy</span><span lang="EN-US">.</span><span lang="EN-US"><?xml:namespace prefix = o /><o:p></o:p></span> </p